Rep. Kevin Hern (R-OK) Sells Boston Scientific (BSX) Stock
Oklahoma Congressman Kevin Hern sold a significant stake in Boston Scientific on September 4, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Kevin Hern (R-OK) sold between $50,001 and $100,000 of Boston Scientific Corporation ($BSX) stock on September 4, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed September 25, 2026.
Since the trade, $BSX is down 10.1% after 1 week, down 11.3% after 1 month and down 7.1% to date (from the $47.80 close on Sep 4, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Kevin Hern (R-OK)
- Status:
- Member — House
- State/District:
- OK-1
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Sep 25, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Sell | Sep 4, 2026 | $50,001 - $100,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- Oklahoma Congressman Kevin Hern sold between $50,001 and $100,000 of Boston Scientific shares on September 4, 2026.
- The stock closed at $44.12 on the day of the sale, down from $43.00 the previous day.
- Hern's recent trades also include the sale of shares from PTC Inc., UnitedHealth Group, and Novo Nordisk.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Oklahoma Congressman Kevin Hern sold between $50,001 and $100,000 of shares in Boston Scientific Corporation (NYSE: BSX) on September 4, 2026. This transaction was reported on September 25, detailing the sale of a notable stake in the medical device company.
Hern's sale comes as he has been active in the stock market, previously selling shares from other companies. The trade aligns with his recent pattern of selling, which included shares in PTC Inc., UnitedHealth Group, and Novo Nordisk A/S.
Kevin Hern vs. the S&P 500
Hypothetical returns from Kevin Hern's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Boston Scientific
Several institutional investors have adjusted their positions in Boston Scientific recently. BlackRock Inc. trimmed its holdings by 2,135,425 shares, leaving it with 129,680,916 shares valued at approximately $5.72 billion. In contrast, State Street Corporation increased its stake by 2,121,285 shares, totaling 70,111,196 shares worth about $3.09 billion. Vanguard Capital Management added 674,889 shares, bringing its total to 97,087,553 shares valued at around $4.28 billion. Primecap Management Company grew its holdings by 17,991,834 shares, ending with 50,520,914 shares worth about $2.23 billion, while FMR, LLC cut its stake significantly by 28,526,236 shares, now holding 45,702,845 shares valued at about $2.02 billion.
Boston Scientific Corporation Stock Up 2.6%
Boston Scientific shares closed at $44.12 on the day of Hern's sale, indicating a slight increase from the previous close of $43.00. The stock has traded between $41.39 and $105.65 over the past year, suggesting it remains well below its 52-week high. This sale could reflect Hern's view on the company's current performance and market conditions.
Recent Earnings
In its last earnings report, Boston Scientific reported revenue of approximately $20.99 billion, showing a revenue growth of 7.5% year-over-year. The company had earnings per share (EPS) of $2.47 and a net margin of about 17.5%. The next earnings date is set for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Analysts Set New Price Targets
On September 24, 2026, Wells Fargo maintained its rating of Equal-Weight on Boston Scientific with a price target of $48.00, down from $50.00. Similarly, Citigroup also maintained its Neutral rating with a target of $48.00 on October 5, 2026, down from $50.00. Additionally, Oppenheimer maintained its Outperform rating with a price target of $65.00 on September 21, 2026, although this was a reduction from its previous target of $85.00. The consensus among analysts is a Buy rating with a mean price target of about $59.24.
About Boston Scientific
Boston Scientific Corporation, based in Marlborough, MA, develops and sells medical devices across various medical specialties. Its products serve vital areas such as interventional cardiology and minimally invasive surgery. Hern's sale of shares may reflect broader market trends affecting the healthcare sector.
Bottom Line
Kevin Hern's sale of Boston Scientific shares adds to his recent trading history, which includes notable transactions involving other companies. Investors will be watching for further details from Hern's future filings and the company's upcoming earnings on October 28, 2026. Remember that this 13F filing reflects past holdings and may not represent current positions.
Related Filing Alerts
Source: Kevin Hern's STOCK Act disclosure on $BSX (Sep 4, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts